Literature DB >> 28115507

Overcoming Hurdles to Development of a Vaccine against Pneumocystis jirovecii.

Beth A Garvy1.   

Abstract

Development of Pneumocystis pneumonia (PCP) is a common problem among immunosuppressed individuals. There are windows of opportunity in which vaccination would be beneficial, but to date, no vaccines have made it to clinical trials. Significant hurdles to vaccine development include host range specificity, making it difficult to translate from animal models to humans. Discovery of cross-reactive epitopes is critical to moving vaccine candidates from preclinical animal studies to clinical trials.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Pneumocystis carinii; vaccines

Mesh：

Substances：

Year:  2017        PMID： 28115507      PMCID： PMC5364313          DOI： 10.1128/IAI.00035-17

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  24 in total

1.  Novel pneumocystis antigen discovery using fungal surface proteomics.

Authors:  Mingquan Zheng; Yang Cai; Taylor Eddens; David M Ricks; Jay K Kolls
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

2.  CD4+ T cell-independent DNA vaccination against opportunistic infections.

Authors:  Mingquan Zheng; Alistair J Ramsay; Myles B Robichaux; Corrine Kliment; Christopher Crowe; Rekha R Rapaka; Chad Steele; Florencia McAllister; Judd E Shellito; Luis Marrero; Paul Schwarzenberger; Qiu Zhong; Jay K Kolls
Journal:  J Clin Invest       Date:  2005-11-23       Impact factor: 14.808

3.  Pneumocystis pneumonia in patients treated with rituximab.

Authors:  Isabel Martin-Garrido; Eva M Carmona; Ulrich Specks; Andrew H Limper
Journal:  Chest       Date:  2013-07       Impact factor: 9.410

Review 4.  Recent innovations in mRNA vaccines.

Authors:  Jeffrey B Ulmer; Andrew J Geall
Journal:  Curr Opin Immunol       Date:  2016-05-26       Impact factor: 7.486

5.  Serologic responses to pneumocystis proteins in HIV patients with and without Pneumocystis jirovecii pneumonia.

Authors:  Matthew R Gingo; Lorrie Lucht; Kieran R Daly; Kpandja Djawe; Frank J Palella; Alison G Abraham; Jay H Bream; Mallory D Witt; Lawrence A Kingsley; Karen A Norris; Peter D Walzer; Alison Morris
Journal:  J Acquir Immune Defic Syndr       Date:  2011-07-01       Impact factor: 3.731

6.  Antibody-mediated shift in the profile of glycoprotein A phenotypes observed in a mouse model of Pneumocystis carinii pneumonia.

Authors:  F Gigliotti; B A Garvy; A G Harmsen
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

7.  Pneumocystis carinii host origin defines the antibody specificity and protective response induced by immunization.

Authors:  F Gigliotti; A G Harmsen
Journal:  J Infect Dis       Date:  1997-11       Impact factor: 5.226

8.  Immunization with the major surface glycoprotein of Pneumocystis carinii elicits a protective response.

Authors:  S A Theus; A G Smulian; P Steele; M J Linke; P D Walzer
Journal:  Vaccine       Date:  1998-07       Impact factor: 3.641

9.  Immunization with Pneumocystis carinii gpA is immunogenic but not protective in a mouse model of P. carinii pneumonia.

Authors:  F Gigliotti; J A Wiley; A G Harmsen
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

10.  Intranasal immunization confers protection against murine Pneumocystis carinii lung infection.

Authors:  J M Pascale; M M Shaw; P J Durant; A A Amador; M S Bartlett; J W Smith; R L Gregory; G L McLaughlin
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.